Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$7.47 +5.5%	$7.16	$3.54 ▼ $8.90	$164.93M	0.8	188,629 shs	239,603 shs
EDIT Editas Medicine	$2.80 +2.6%	$2.63	$0.91 ▼ $4.12	$245.48M	2.19	2.07 million shs	1.46 million shs
SXTC China SXT Pharmaceuticals	$1.57	$1.68	$0.95 ▼ $7.84	$182.16M	1.24	40,649 shs	17,398 shs
XCUR Exicure	$6.09 -1.8%	$7.05	$1.44 ▼ $36.00	$39.17M	3.67	73,592 shs	8,762 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	+5.51%	+7.48%	+1.08%	+6.71%	+69.77%
EDIT Editas Medicine	+2.56%	-7.59%	-19.08%	+80.65%	-31.37%
SXTC China SXT Pharmaceuticals	0.00%	-2.48%	-7.10%	+1.29%	-77.18%
XCUR Exicure	-1.77%	-8.42%	-27.33%	-39.34%	+1,480.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DERM Journey Medical	1.676 of 5 stars	3.2	1.0	0.0	2.3	0.8	0.6
EDIT Editas Medicine	4.2389 of 5 stars	3.1	4.0	4.3	1.5	2.5	0.6
SXTC China SXT Pharmaceuticals	0.7742 of 5 stars	0.0	3.0	0.0	3.3	0.0	0.6
XCUR Exicure	1.9208 of 5 stars	0.0	5.0	4.7	2.2	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DERM Journey Medical	2.33	Hold	$11.75	57.30% Upside
EDIT Editas Medicine	2.23	Hold	$5.10	82.14% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A
XCUR Exicure	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest XCUR, DERM, EDIT, and SXTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $5.00
8/15/2025	DERM Journey Medical	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/13/2025	DERM Journey Medical	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $13.00
8/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $6.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DERM Journey Medical	$56.13M	3.10	N/A	N/A	$0.83 per share	9.00
EDIT Editas Medicine	$32.31M	7.79	N/A	N/A	$0.21 per share	13.33
SXTC China SXT Pharmaceuticals	$1.74M	104.69	N/A	N/A	$21.35 per share	0.07
XCUR Exicure	$500K	76.98	N/A	N/A	$1.40 per share	4.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DERM Journey Medical	-$14.67M	-$0.38	N/A	N/A	N/A	-15.49%	-48.69%	-11.26%	11/11/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$2.85	N/A	N/A	N/A	-608.88%	-200.25%	-68.57%	11/3/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	-$9.70M	-$3.88	N/A	∞	N/A	N/A	-192.16%	-84.30%	N/A

Latest XCUR, DERM, EDIT, and SXTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	DERM Journey Medical	-$0.07	-$0.16	-$0.09	-$0.16	$14.93 million	$15.01 million
8/12/2025	Q2 2025	EDIT Editas Medicine	-$0.41	-$0.63	-$0.22	-$0.63	$1.81 million	$3.58 million
8/8/2025	Q2 2025	XCUR Exicure	N/A	-$0.41	N/A	-$0.41	N/A	N/A
6/27/2025	Q1 2025	XCUR Exicure	N/A	-$0.45	N/A	$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DERM Journey Medical	1.11	1.27	0.95
EDIT Editas Medicine	N/A	2.77	2.77
SXTC China SXT Pharmaceuticals	0.01	3.54	3.40
XCUR Exicure	N/A	1.89	1.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DERM Journey Medical	7.25%
EDIT Editas Medicine	71.90%
SXTC China SXT Pharmaceuticals	5.02%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
DERM Journey Medical	15.03%
EDIT Editas Medicine	2.10%
SXTC China SXT Pharmaceuticals	3.95%
XCUR Exicure	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DERM Journey Medical	90	23.30 million	19.80 million	N/A
EDIT Editas Medicine	230	89.92 million	88.03 million	Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable
XCUR Exicure	50	6.32 million	6.07 million	Not Optionable

XCUR, DERM, EDIT, and SXTC Headlines

Recent News About These Companies

Short Interest in Exicure, Inc. (NASDAQ:XCUR) Drops By 51.8%

August 18, 2025 | americanbankingnews.com

Exicure Posts Wider Loss in Fiscal Q2

August 8, 2025 | aol.comA

Exicure, Inc. Reports Second Quarter 2025 Financial Results | XCUR Stock News

August 8, 2025 | gurufocus.com

Exicure, Inc. Reports Second Quarter 2025 Financial Results

August 8, 2025 | businesswire.com

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

August 4, 2025 | businesswire.com

Stocks to Watch: Exicure, TTEC

August 3, 2025 | marketwatch.com

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

August 1, 2025 | businesswire.com

XCUR | Exicure Inc. Annual Cash Flow Statement - MarketWatch

July 19, 2025 | marketwatch.com

Is Exicure Stock (XCUR) Experiencing a Dead Cat Bounce?

June 30, 2025 | msn.com

Exicure Shares Up After Swing to Profit in 1Q

June 27, 2025 | marketwatch.com

Exicure, Inc. Reports First Quarter 2025 Financial Results

June 27, 2025 | businesswire.com

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

May 28, 2025 | businesswire.com

Why Exicure Inc. (XCUR) Soared on Monday

April 22, 2025 | msn.com

Exicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myeloma

April 16, 2025 | pharmabiz.comP

Exicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100

April 15, 2025 | pharmabiz.comP

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

April 14, 2025 | businesswire.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...

April 11, 2025 | gurufocus.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025 | investing.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025 | businesswire.com

Wednesday’s Insider Moves: Top Buys and Sells in US Stocks

March 27, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, DERM, EDIT, and SXTC Company Descriptions

Journey Medical NASDAQ:DERM

$7.47 +0.39 (+5.51%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.49 +0.02 (+0.27%)

As of 08/22/2025 04:10 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Editas Medicine NASDAQ:EDIT

$2.80 +0.07 (+2.56%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.80 +0.01 (+0.18%)

As of 08/22/2025 07:51 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.57 0.00 (0.00%)

Closing price 08/22/2025 03:55 PM Eastern

Extended Trading

$1.57 +0.00 (+0.25%)

As of 08/22/2025 04:12 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Exicure NASDAQ:XCUR

$6.09 -0.11 (-1.77%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$6.07 -0.02 (-0.33%)

As of 08/22/2025 05:59 PM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time